Outlook Therapeutics
OTLK
15 hedge funds and large institutions have $3.32M invested in Outlook Therapeutics in 2018 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.01% less ownership
Funds ownership: 0.1% → 0.09% (-0.01%)
12% less funds holding
Funds holding: 17 → 15 (-2)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
33% less capital invested
Capital invested by funds: $4.96M → $3.32M (-$1.64M)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$37.7K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$32.3K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.22K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$5.36K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$40K |
| 2 |
VF
Virtu Financial
New York
|
-$37K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$35.2K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$32K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$30K |
OTLK Hedge Fund Activity: Q1 2018 in Review
15 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q1 2018, worth a combined $3.32M — down 33% from $4.96M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of OTLK and 1 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $37.7K. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $40K sold.
- 15 institutional investors held Outlook Therapeutics (OTLK) as of Q1 2018, down from 17 in Q4 2017.
- Funds reported $3.32M of Outlook Therapeutics stock for Q1 2018, down 33% quarter-over-quarter.
- 1 fund opened new Outlook Therapeutics positions in Q1 2018 and 3 closed out, a net change of -2 holders.
- The largest Outlook Therapeutics buyer in Q1 2018 was Susquehanna International Group, an estimated $37.7K added.
- The largest Outlook Therapeutics seller in Q1 2018 was Cormorant Asset Management, an estimated $40K sold.
Based on aggregated 13F filings for Q1 2018.